series-c-plus
Stage
2018
Founded
2
Investors
About
Highlight Therapeutics is a clinical-stage biotechnology company developing a new class of RNA-based drugs (DRP) for cancer treatment. Their lead product, BO-112, targets solid tumors like melanoma, lung, and liver cancer.
Explore Highlight Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.